Show simple item record

dc.contributor.authorSepulveda-Crespo, Daniel 
dc.contributor.authorResino, Salvador 
dc.contributor.authorMartinez, Isidoro 
dc.date.accessioned2020-08-10T08:31:46Z
dc.date.available2020-08-10T08:31:46Z
dc.date.issued2020-06-17
dc.identifier.citationVaccines (Basel) . 2020 Jun 17;8(2):313.es_ES
dc.identifier.issn2076-393Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10873
dc.description.abstractDespite successful treatments, hepatitis C virus (HCV) infections continue to be a significant world health problem. High treatment costs, the high number of undiagnosed individuals, and the difficulty to access to treatment, particularly in marginalized susceptible populations, make it improbable to achieve the global control of the virus in the absence of an effective preventive vaccine. Current vaccine development is mostly focused on weakly immunogenic subunits, such as surface glycoproteins or non-structural proteins, in the case of HCV. Adjuvants are critical components of vaccine formulations that increase immunogenic performance. As we learn more information about how adjuvants work, it is becoming clear that proper stimulation of innate immunity is crucial to achieving a successful immunization. Several hepatic cell types participate in the early innate immune response and the subsequent inflammation and activation of the adaptive response, principally hepatocytes, and antigen-presenting cells (Kupffer cells, and dendritic cells). Innate pattern recognition receptors on these cells, mainly toll-like receptors, are targets for new promising adjuvants. Moreover, complex adjuvants that stimulate different components of the innate immunity are showing encouraging results and are being incorporated in current vaccines. Recent studies on HCV-vaccine adjuvants have shown that the induction of a strong T- and B-cell immune response might be enhanced by choosing the right adjuvant.es_ES
dc.description.sponsorshipPI17CIII/00003/Instituto de Salud Carlos III PI19CIII/00009/Instituto de Salud Carlos III RD16CIII/0002/0002/Plan Nacional R+D+Ies_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.isversionofPreprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshHCVes_ES
dc.subject.meshPRRses_ES
dc.subject.meshadjuvantes_ES
dc.subject.meshinnate immune responsees_ES
dc.subject.meshvaccinees_ES
dc.titleInnate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32560440es_ES
dc.format.volume8es_ES
dc.format.number2es_ES
dc.identifier.doi10.3390/vaccines8020313es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines8020313es_ES
dc.identifier.journalVaccineses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17CIII/00003es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI19CIII/00009es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional